A Disclosure Requirement in Patent Law

The Issue

Some members of the international community, including a number of developing countries, have expressed concern that the patent system promotes “biopiracy” (i.e. the unauthorised use without compensation of biological resources by third parties) contrary to the objectives of the Convention on Biological Diversity (CBD). Paragraph 19 of the WTO Doha Declaration of November 2001 therefore directed the TRIPS Council “to examine the relationship between TRIPS Agreement and the Convention on Biological Diversity, protection of traditional knowledge and folklore”.

One of the main demands of those who believe there is a problem is the introduction of a patent-based “solution” whereby patent applications would have to disclose any or all of the following: (i) the origin of genetic resources used in the invention; (ii) evidence of prior informed consent from the relevant national authority to access and use genetic resources; and (iii) evidence of fair and equitable sharing of the benefits derived from the genetic resource.

It is argued that such a disclosure requirement within the patent system would promote the CBD objectives namely, the conservation of biological diversity and the fair and equitable access & benefit sharing (ABS) and would help prevent biopiracy. This argument is deeply flawed. In fact, such a requirement, particularly if coupled with a significant sanction for breach (including patent invalidation) would not only fail to support the CBD objectives, it would actively undermine the pharmaceutical industry’s willingness to engage in R&D involving anything that may be regarded as being derived from genetic resources. This scenario would be bad for patients (as fewer new medicines would be forthcoming) and bad for countries which are the source of genetic resources (as there would be fewer benefits to be shared). This paper expands upon these dangers and GSK’s belief that local laws which facilitate access to, and use of, genetic resources in R&D are the most effective way of realising the CBD’s ABS objectives.

GSK’s Position

– GSK supports the CBD objective “to provide fair and equitable sharing of the benefits arising from the use of genetic resources”.

– There is limited evidence of “biopiracy” and even less that it is somehow facilitated by the patent system. As such, there is no evidence that it would be reduced by new disclosure obligations in patent applications.

– The patent system was designed to promote innovation and thereby to promote economic development. It was not designed to regulate or enforce rules relating to conduct.

– The difficulty of defining the precise scope of any disclosure obligation would create significant legal uncertainties for researchers and those who develop commercial products.

– These legal uncertainties would reduce incentives to develop products which in any way involve “genetic resources”. This would lead to a reduction in innovation and the societal benefits that arise from it. It would also frustrate the ABS objectives of the CBD because if there is less research, there will be fewer benefits to share.

– The CBD provides a clear mandate for Governments to establish ABS provisions in their national laws for users and owners of genetic resources. Where local laws exist, they are generally new and it is too early to assess their impact. GSK believes that once countries have adopted local laws which facilitate use of genetic resources in R&D, as is mandated by the CBD, they will receive the benefits envisaged under the CBD. To introduce a disclosure obligation now would, at best, be premature and at worse, highly damaging to innovation and public health.

– To date, discussions within international institutions (including the WTO and WIPO) around the practical implications of a disclosure requirement have failed to reach any concrete conclusions and consensus.
This failure reflects the fact that many (including GSK) believe that a disclosure obligation will not support the objectives of the CBD. It may well undermine them, as well as act as a brake on innovation.

Background

The Convention on Biological Diversity

The Convention on Biological Diversity (CBD) agreed in 1992 sets out commitments for maintaining the world's ecological systems. It establishes three main goals: (1) the conservation of biological diversity, (2) the sustainable use of its components, and (3) the fair and equitable sharing of the benefits from the use of genetic resources.

The CBD does not suggest or require that countries modify their patent laws in any way; it does not require, or even mention, patent disclosure requirements. It provides a framework which Governments are encouraged to adopt in support of ABS.

The Nagoya Protocol

In October 2010, agreement was reached around the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilisation. The Protocol reaffirms the importance of legal certainty, clarity and transparency in systems regulating access to genetic resources and the fair and equitable sharing of benefits from their use. Importantly, like the CBD, it does not mention a disclosure obligation as a possible compliance mechanism and it affirms the key principle in the CBD that the terms associated with access and benefit sharing should be mutually agreed by the provider and user of the genetic resources.

WIPO and a Disclosure Obligation

Discussions about a disclosure obligation have been ongoing within the expert arena of the World Intellectual Property Organisation (WIPO) since 2000. Numerous reports and technical studies have been prepared by various expert working groups. No conclusions have yet been reached as negotiators disagree as to whether an obligation will support CBD objectives and continue to grapple with issues of scope, definition and enforcement. The length and inconclusive nature of these negotiations underscore the sheer complexity of the issues involved. And how the international community should not rush to introduce an obligation, the implications and scope of which are so unclear.

The Alleged Objective of the Proposed Disclosure Requirement

Despite the agreement reached around the Nagoya Protocol, some stakeholders continue to argue that the CBD’s objectives would be more effectively promoted via the introduction of a disclosure obligation in TRIPs. They argue that a formal obligation – coupled with significant sanctions for non-compliance, including patent invalidation - would assist in ensuring and monitoring performance of CBD objectives, particularly compliance with local laws. In other words, they argue that these requirements would help prevent “biopiracy” by third parties (including the private sector).

The scale and nature of the alleged “biopiracy” problem however have not been identified or substantiated. This alone draws into question whether or how a disclosure obligation could alleviate any ‘biopiracy’.

Arguments Against a Disclosure Requirement

1) It would not support the CBD’s objectives

- It would not support prior informed consent provisions: If the goal is to ensure authorised access based on prior informed consent, only local laws governing access to genetic resources, preferably coupled to contracts that clearly establish the rights and obligations of the entities involved prior to any access to genetic resources, can ensure this. A disclosure requirement in patent law would not.
– It would not promote benefit sharing where no relevant patents exist: A disclosure requirement would not address problems associated with any access and use of resources under the CBD which do not lead to patent applications. Many researchers never use accessed genetic resources to develop commercial products and will not file patent applications. In such situations, uses of genetic resources could occur that would yield “benefits” that should theoretically be shared with the country of origin. However, these uses would not be linked in any way to a patent application. A patent disclosure requirement would therefore do nothing in these cases to promote benefit sharing.

– It would not promote benefit sharing where patents do exist: Even where patents do exist as a result of access and use of resources under the CBD, it is the ABS agreement that promotes benefit sharing, not compliance with a disclosure obligation.

2) It would not help to monitor compliance with local laws

The vast majority of undertakings (commercial or otherwise) take great pains to abide by local laws and perform their contractual undertakings. Providing a clear local legal framework controlling access to genetic resources and ABS agreements will, in the vast majority of cases, be the most effective and self-policing method of ensuring compliance with local laws and fulfillment of CBD objectives.

On the rare occasions where a company has deliberately failed to comply with its obligations relating to access and benefit sharing, it is hardly likely to incriminate itself by drawing attention to this fact by disclosing the use of genetic material in a patent application.

Furthermore, any economic benefits arising from use of the patent system may not occur for many years after access to the resource, assuming any economic return occurs at all. This is likely to make effective third-party monitoring of the appearance of commercial products which might be associated with a particular patent application over a period of many years extremely challenging. Monitoring under these circumstances will most appropriately and feasibly be conducted under the auspices of an ABS Agreement.

3) It would create legal uncertainty

Before committing resources to research, companies ask themselves whether they can clearly identify what their obligations relating to that research and its outcomes are. If the scope of an obligation is unclear in practice and the sanction for breach of the obligation is significant, companies will be reluctant to undertake research. To date, as demonstrated by the ongoing discussions within WIPO and the EU, it is clear that many significant questions in relation to disclosure requirements and the practical implications of the answers to those questions, have not been adequately addressed or understood. For example:

– What connection is needed between the genetic resource and the invention to give rise to the disclosure obligation? Genetic resources, both human and non-human, are used throughout medical research. For example, there are cases where a genetic resource might be the starting point from which the patented end product is ultimately derived. However, the end product will generally be a synthetic or isolated form of the genetic material and will usually involve a significant variation or modification of the genetic resource in its natural, isolated or synthesised form. The end product disclosed in the patent may bear little relationship to the starting point. Should there be disclosure when the product is modified and how much modification is needed before the disclosure obligation ceases? Proposals to describe the link between the genetic resource and the invention in terms such as “directly based” or “make immediate use of” give insufficient practical guidance, far less an acceptable degree of certainty, to those involved in the innovation process.

– Genetic resources will often be used as “tools” in either the R&D process (eg research animals) or manufacturing process (eg yeasts) leading to an end product but will not be part of the end product itself. Should the origin of such “tools” be disclosed in a patent application for the end product?

– Companies will routinely conduct large scale screening programmes involving thousands of genetic resources to see if any of their chemical/synthetic compounds successfully act against any of the genetic resources (eg viruses or bacteria). Should companies be expected to put in place ABS agreements for each genetic resource used in these screening programmes, let alone expected to disclose their origin in any subsequent patent applications?
It is vital that all these questions are answered in a way clear enough to enable those using genetic resources to accurately assess, in practice, whether an obligation to disclose the origin of a genetic resource arises. If an international obligation to disclose is not framed with a great deal of practical clarity, it will be implemented and interpreted in national laws in different ways, creating multiple uncertainties and different obligations for researchers. It could also lead to abuse of the patent system in an attempt to achieve national objectives which go far beyond any legitimate interpretation of the CBD.

Even if these questions can be answered, satisfying a requirement may be extremely difficult in practice. Depending on the nature of the obligation, particularly if it is introduced retrospectively, it may simply be impossible or impractical to trace the origin of the genetic resource. And if the material is not the genetic resource but something derived from it, the fact that it was derived from a genetic resource may not even be known. Faced with uncertainty as to whether the material is covered by a disclosure obligation, researchers may simply not proceed and innovation will be impeded.

4) It would adversely impact on innovation and therefore on any “benefits” to be shared

As stated earlier, companies and others who invest in research must have certainty as to what is needed to ensure the legal security of that investment. Although there is inherent commercial risk in any research in the sense that it may not lead to a commercially viable product, legal risk that the fruits of successful investment can, in effect, be removed on grounds of failure to comply with legal requirements should be minimal if research is to be undertaken. As the degree of legal certainty of a disclosure requirement decreases and its potential scope and the consequences of sanctions increase, the likelihood of companies like GSK investing in the development of genetic resources will decrease. As investment decreases, the likelihood of innovation, and of benefits accruing from innovation, is diminished. A disclosure obligation which leads to a reduction in innovation and benefit sharing would be of no benefit to society and would run contrary to the benefit sharing objectives of the CBD.

The Solution Envisaged by the CBD

The CBD envisages that national laws will promote ABS and that they should be specifically designed to facilitate ABS on mutually agreed terms. Such laws can include provisions that allow for the witting or unwitting breach of the agreed terms and that will secure, not undermine, the benefits to the source country.

Proponents of new disclosure requirements acknowledge that they would not substitute for but would supplement (and ensure the effective enforcement of) national ABS regimes. However, many CBD members have not yet implemented national ABS regimes which facilitate access. Under these circumstances, it is difficult to see how any disclosure requirements can be designed to supplement national legislation that is not in place in the majority of Members.

Proponents of a disclosure obligation also argue that it would help address the lack of a formal mechanism to ensure cross-border compliance with national ABS laws. However, Article 15 of the Nagoya Protocol contains obligations intended to address this issue. Specifically, Parties to the Protocol are required to take “appropriate, effective and proportionate” measures to ensure that any genetic resources used in their jurisdiction have been accessed elsewhere in accordance with Prior Informed Consent (PIC) and that ABS has been on mutually agreed terms.

February 2019